BR112014013723A2 - formas cristalinas da [(s)-1-carbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amida do ácido 2-(2-metil-amino-pirimidin-4-il)-1h-indol-5-carboxílico - Google Patents
formas cristalinas da [(s)-1-carbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amida do ácido 2-(2-metil-amino-pirimidin-4-il)-1h-indol-5-carboxílicoInfo
- Publication number
- BR112014013723A2 BR112014013723A2 BR112014013723A BR112014013723A BR112014013723A2 BR 112014013723 A2 BR112014013723 A2 BR 112014013723A2 BR 112014013723 A BR112014013723 A BR 112014013723A BR 112014013723 A BR112014013723 A BR 112014013723A BR 112014013723 A2 BR112014013723 A2 BR 112014013723A2
- Authority
- BR
- Brazil
- Prior art keywords
- amino
- pyrimidin
- carbamoyl
- phenyl
- ethyl
- Prior art date
Links
- -1 2-methyl-amino-pyrimidin-4-yl Chemical group 0.000 title 1
- ROSHAFRDSNTIKP-NSHDSACASA-N (2s)-2-amino-3-(n-pyrimidin-2-ylanilino)propanamide Chemical compound N=1C=CC=NC=1N(C[C@H](N)C(N)=O)C1=CC=CC=C1 ROSHAFRDSNTIKP-NSHDSACASA-N 0.000 abstract 1
- JKSPMBDXZPKQNC-KTQQKIMGSA-N C(N)(=O)[C@H](CN(C1=NC=CC=N1)C1=CC=CC=C1)NC(=O)C1(NC=CC(=N1)N)C Chemical compound C(N)(=O)[C@H](CN(C1=NC=CC=N1)C1=CC=CC=C1)NC(=O)C1(NC=CC(=N1)N)C JKSPMBDXZPKQNC-KTQQKIMGSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
resumo patente de invenção: "formas cristalinas da [(s)-1-carbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amida do ácido 2-(2-metil-amino-pirimidin-4-il)-1h-indol-5-carboxílico". a presente invenção refere-se a polimorfos e hidratos da [(s)-1-carbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amida do ácido 2-(2-metil-amino-pirimidin-4-il)-1h-indol-5-carboxílico, a processos para sua preparação e seu uso, em particular em composições farmacêuticas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11306618 | 2011-12-06 | ||
| PCT/EP2012/074339 WO2013083553A1 (en) | 2011-12-06 | 2012-12-04 | Crystalline forms of 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014013723A8 BR112014013723A8 (pt) | 2017-06-13 |
| BR112014013723A2 true BR112014013723A2 (pt) | 2017-06-13 |
Family
ID=47278314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014013723A BR112014013723A2 (pt) | 2011-12-06 | 2012-12-04 | formas cristalinas da [(s)-1-carbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amida do ácido 2-(2-metil-amino-pirimidin-4-il)-1h-indol-5-carboxílico |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9067918B2 (pt) |
| EP (1) | EP2787998B1 (pt) |
| JP (1) | JP6078551B2 (pt) |
| KR (1) | KR20140103968A (pt) |
| CN (1) | CN104105483B (pt) |
| AR (1) | AR089078A1 (pt) |
| AU (1) | AU2012347393B2 (pt) |
| BR (1) | BR112014013723A2 (pt) |
| CA (1) | CA2856607C (pt) |
| CY (1) | CY1118615T1 (pt) |
| DK (1) | DK2787998T3 (pt) |
| ES (1) | ES2612217T3 (pt) |
| HR (1) | HRP20170092T1 (pt) |
| HU (1) | HUE031525T2 (pt) |
| IL (1) | IL232693B (pt) |
| LT (1) | LT2787998T (pt) |
| MX (1) | MX351994B (pt) |
| PL (1) | PL2787998T3 (pt) |
| PT (1) | PT2787998T (pt) |
| RU (1) | RU2631320C2 (pt) |
| SG (1) | SG11201402461RA (pt) |
| SI (1) | SI2787998T1 (pt) |
| UY (1) | UY34497A (pt) |
| WO (1) | WO2013083553A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3184095A1 (en) | 2013-05-23 | 2017-06-28 | IP Gesellschaft für Management mbH | Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide |
| ES2697806T3 (es) * | 2014-07-03 | 2019-01-28 | Sanofi Sa | [(S)-1-carbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amida del ácido 2-(2-metilamino-pirimidin-4-il)-1H-indol-5-carboxílico para uso en el tratamiento de dolor asociado a artrosis |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10237723A1 (de) * | 2002-08-17 | 2004-07-08 | Aventis Pharma Deutschland Gmbh | Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie |
| US7462638B2 (en) * | 2002-08-17 | 2008-12-09 | Sanofi-Aventis Deutschland Gmbh | Use of IκB-kinase inhibitors in pain therapy |
| DE10237722A1 (de) * | 2002-08-17 | 2004-08-19 | Aventis Pharma Deutschland Gmbh | Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase |
| AR053114A1 (es) * | 2005-01-12 | 2007-04-25 | Aventis Pharma Inc | Sal monopotasica del acido 2-{[2-(-2-metilamino-pirimidin-4-il)-1h-indol-5-carbonil]-amino}-3-(fenilpiridin-2-il-amino)-propionico,inhibidora de ikk-2 quinasa |
| DE102005025225A1 (de) | 2005-06-01 | 2006-12-07 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten |
| JP2012520257A (ja) * | 2009-03-10 | 2012-09-06 | グラクソ グループ リミテッド | Ｉｋｋ２阻害剤としてのインドール誘導体 |
| CN103209961A (zh) | 2010-08-12 | 2013-07-17 | 赛诺菲 | 用于制备2,3-二氨基丙酸衍生物的对映异构体形式的方法 |
| PE20131351A1 (es) * | 2010-09-30 | 2013-12-04 | Boehringer Ingelheim Int | Formas en estado solido de un potente inhibidor del vch |
-
2012
- 2012-12-04 CN CN201280068949.4A patent/CN104105483B/zh active Active
- 2012-12-04 JP JP2014545202A patent/JP6078551B2/ja active Active
- 2012-12-04 US US14/363,146 patent/US9067918B2/en active Active
- 2012-12-04 EP EP12794728.1A patent/EP2787998B1/en active Active
- 2012-12-04 RU RU2014127478A patent/RU2631320C2/ru active
- 2012-12-04 PT PT127947281T patent/PT2787998T/pt unknown
- 2012-12-04 SG SG11201402461RA patent/SG11201402461RA/en unknown
- 2012-12-04 ES ES12794728.1T patent/ES2612217T3/es active Active
- 2012-12-04 AR ARP120104550A patent/AR089078A1/es unknown
- 2012-12-04 HR HRP20170092TT patent/HRP20170092T1/hr unknown
- 2012-12-04 MX MX2014006838A patent/MX351994B/es active IP Right Grant
- 2012-12-04 PL PL12794728T patent/PL2787998T3/pl unknown
- 2012-12-04 SI SI201230840A patent/SI2787998T1/sl unknown
- 2012-12-04 DK DK12794728.1T patent/DK2787998T3/en active
- 2012-12-04 BR BR112014013723A patent/BR112014013723A2/pt not_active Application Discontinuation
- 2012-12-04 LT LTEP12794728.1T patent/LT2787998T/lt unknown
- 2012-12-04 HU HUE12794728A patent/HUE031525T2/en unknown
- 2012-12-04 KR KR1020147016860A patent/KR20140103968A/ko not_active Ceased
- 2012-12-04 CA CA2856607A patent/CA2856607C/en active Active
- 2012-12-04 WO PCT/EP2012/074339 patent/WO2013083553A1/en active Application Filing
- 2012-12-04 AU AU2012347393A patent/AU2012347393B2/en active Active
- 2012-12-06 UY UY0001034497A patent/UY34497A/es not_active Application Discontinuation
-
2014
- 2014-05-19 IL IL232693A patent/IL232693B/en active IP Right Grant
-
2017
- 2017-02-08 CY CY20171100178T patent/CY1118615T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013083553A1 (en) | 2013-06-13 |
| LT2787998T (lt) | 2017-02-10 |
| IL232693B (en) | 2018-07-31 |
| MX2014006838A (es) | 2014-11-25 |
| CY1118615T1 (el) | 2017-07-12 |
| RU2631320C2 (ru) | 2017-09-21 |
| UY34497A (es) | 2013-07-31 |
| US9067918B2 (en) | 2015-06-30 |
| KR20140103968A (ko) | 2014-08-27 |
| RU2014127478A (ru) | 2016-02-10 |
| SG11201402461RA (en) | 2014-08-28 |
| AU2012347393B2 (en) | 2017-06-08 |
| IL232693A0 (en) | 2014-07-31 |
| JP6078551B2 (ja) | 2017-02-08 |
| JP2015500255A (ja) | 2015-01-05 |
| EP2787998A1 (en) | 2014-10-15 |
| MX351994B (es) | 2017-11-06 |
| DK2787998T3 (en) | 2017-02-06 |
| CA2856607A1 (en) | 2013-06-13 |
| BR112014013723A8 (pt) | 2017-06-13 |
| AU2012347393A1 (en) | 2014-06-19 |
| EP2787998B1 (en) | 2016-11-09 |
| CN104105483B (zh) | 2017-03-22 |
| CN104105483A (zh) | 2014-10-15 |
| US20140336211A1 (en) | 2014-11-13 |
| PL2787998T3 (pl) | 2017-04-28 |
| CA2856607C (en) | 2020-03-10 |
| SI2787998T1 (sl) | 2017-02-28 |
| HUE031525T2 (en) | 2017-07-28 |
| HRP20170092T1 (hr) | 2017-03-24 |
| ES2612217T3 (es) | 2017-05-12 |
| PT2787998T (pt) | 2017-01-03 |
| AR089078A1 (es) | 2014-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014011162A2 (pt) | derivados purínicos para o tratamento de infecções virais | |
| BR112015011036A2 (pt) | derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais | |
| BR112014011594A2 (pt) | anticorpos anti-il-36r | |
| UA109010C2 (en) | Morpholino pyrividines and their use in therapy | |
| IL233200A0 (en) | The history of alpha-boronic acid, its preparation and pharmaceutical preparations containing it | |
| EA201391719A1 (ru) | Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
| PT2344198T (pt) | Preparações farmacêuticas à base de lípidos para aplicação tópica | |
| UY32174A (es) | Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones | |
| BR112013020352A2 (pt) | composto, composição farmacêutica, uso de um composto e método para tratar doença ou condição mediana por rorgamat num indivíduo | |
| BR112015000615A2 (pt) | purinas macrocíclicas para o tratamento de infecções virais | |
| PL3517539T3 (pl) | Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II | |
| BR112013016772A2 (pt) | composto, uso do composto, composição farmacêutica, oligonucleotídeo e conjugado | |
| HUE046557T2 (hu) | Tapentadolt tartalmazó vizes gyógyszerészeti készítmény szájon át alkalmazásra | |
| BR112015007366A2 (pt) | derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças | |
| CL2012003075A1 (es) | Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion. | |
| BR112014005025A2 (pt) | composição farmacêutica para uso no tratamento de uma doença neurodegenerativa | |
| UA103025C2 (ru) | Твердая композиция лекарственного средства замедленного высвобождения | |
| EA201200616A1 (ru) | Производные 2-оксо-1-пирролидинилимидазотиадиазола | |
| BR112014005935A2 (pt) | derivados de anilina, sua preparação e sua aplicação terapêutica | |
| GT201300084A (es) | Conjugado de naloxol-peg cristalino | |
| UA110979C2 (uk) | Рідка фармацевтична композиція, яка включає нітизинон | |
| IL227404A0 (en) | Pyrimidine history, their preparation and pharmaceutical preparations containing them | |
| EA201291014A1 (ru) | Трициклическое индазольное соединение, способ его получения и содержащая его фармацевтическая композиция | |
| BR112014009760A2 (pt) | análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo | |
| BR112014001425A2 (pt) | forma de dosagem farmacêutica, composição farmacêutica, e, composto (i) ou sal farmaceuticamente aceitável do mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |